Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Gene | ABL1 |
| Variant | fusion |
| Impact List | fusion |
| Protein Effect | unknown |
| Gene Variant Descriptions | ABL1 fusion indicates a fusion of the ABL1 gene, but the fusion partner is unknown. |
| Associated Drug Resistance | |
| Category Variants Paths |
ABL1 mutant ABL1 rearrange ABL1 fusion |
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|---|---|---|---|---|---|
| NCT06124157 | Phase III | Blinatumomab + Dasatinib Imatinib Methotrexate Pegaspargase Thioguanine Cytarabine Mercaptopurine Leucovorin Dasatinib Blinatumomab + Imatinib Prednisone Daunorubicin Doxorubicin Prednisolone Cyclophosphamide | A Study Testing the Combination of Dasatinib or Imatinib to Chemotherapy Treatment With Blinatumomab for Children, Adolescents, and Young Adults With Philadelphia Chromosome Positive (Ph+) or ABL-Class Philadelphia Chromosome-Like (Ph-Like) B-cell Acute Lymphoblastic Leukemia (B-ALL) | Recruiting | USA | CAN | 1 |
| NCT05751044 | Phase Ib/II | Cyclophosphamide + Cytarabine + Dasatinib + Dexamethasone + Venetoclax | HEM-iSMART-B: Dasatinib + Venetoclax + Dexamethasone + Cyclophosphamide and Cytarabine in Pediatric Patients With Relapsed or Refractory Hematological Malignancies (HEM-iSMART B) | Recruiting | SWE | NOR | NLD | ITA | ISR | IRL | GBR | FRA | FIN | ESP | DNK | DEU | BEL | AUT | 0 |